Pemgarda (pemivibart)



Infusion Office Preference:	
PATIENT INFORMATION	
Date: Patient Name:	DOB:
□ NKDA Allergies:	
PROVIDER INFORMATION	
Office Contact Name:	Office Email:
<u> </u>	Provider NPI:
	City: State: Zip:
Office Phone Number:	Office Fax Number:
DIAGNOSIS /ICD 10	
☐ Moderate to severe immune compromise d/t a medical condition or receipt of immunosuppressive	
medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination and :	
Not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual with SARS-CoV-2	
ICD-10 Code (required): ICD-10 Description:	
REQUIRED DOCUMENTATION/Testing	
☐ This signed order form by the provider	☐ Clinical/Progress notes supporting diagnosis above
☐ Patient demographics AND insurance information	☐ Verification that patient has not had severe hypersensitivity reaction to a COVID-19 vaccine
MEDICATION ORDERS	
☐ 4500mg iv one-time infusion over 60 minutes using 0.2micron inline filter	
\square 4500mg iv every 3 months over 60 minutes using 0.2micron inline filter	
Patients must be monitored for 2 hours after the infusion.	
Provider Name (Print) Physician Signature: Date:	